TABLE 6.
Univariate and multivariate Cox regression analyses exploring prognostic factors for OS in mCRPC patients receiving AA treatment
| Variables | OS | |||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age (years) | 1.044 (1.004–1.086) | 0.031 | 1.065 (1.021–1.110) | 0.004 |
| BMI (kg/m2) | 1.012 (0.903–1.135) | 0.834 | – | – |
| ECOG score (0/1 vs. 2) | 0.875 (0.455–1.679) | 0.687 | – | – |
| ISUP grading group | ||||
| 1 | Ref | – | – | |
| 2 | 1.779 (0.368–8.600) | 0.474 | ||
| 3 | 2.389 (0.535–10.668) | 0.254 | ||
| 4 | 3.277 (0.754–14.235) | 0.113 | ||
| 5 | 1.971 (0.359–10.806) | 0.435 | ||
| Clinical T stage | ||||
| 2 | Ref | – | – | |
| 3 | 0.483 (0.225–1.036) | 0.061 | ||
| 4 | 0.549 (0.251–1.200) | 0.133 | ||
| PSA at AA start (ng/ml) | 0.998 (0.979–1.018) | 0.879 | – | – |
| PSA nadir after AA (ng/ml) | 1.055 (1.026–1.084) | <0.001 | 1.045 (1.014–1.077) | 0.004 |
| ADT duration (<12 vs. ≥12 months) | 0.315 (0.164–0.605) | 0.001 | – | 0.148 |
| Metastatic sites (bone only vs. viscera) | 1.637 (0.892–3.006) | 0.112 | – | 0.623 |
| SMI (low vs. high) | 0.200 (0.098–0.406) | <0.001 | 0.250 (0.119–0.524) | <0.001 |
| PPFA/PA (low vs. high) | 4.005 (2.151–7.459) | <0.001 | 3.204 (1.696–6.053) | <0.001 |
Abbreviations: AA, abiraterone acetate; ADT, androgen deprivation therapy; BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance status score; HR, hazard ratio; ISUP, International Society of Urological Pathology; mCRPC, metastatic castration‐resistant prostate cancer; OS, overall survival; PPFA/PA, periprostatic fat area/prostate area; PSA, prostate‐specific antigen; SMI, skeletal muscle index.